Congress moves to ban abortion pill, opens manufacturers to unlimited lawsuits

What it does

This bill would immediately withdraw FDA approval of mifepristone (the abortion pill) for pregnancy termination and create a federal private right of action allowing any woman who uses it to sue the manufacturer for any bodily injury or mental health harm she attributes to the drug, including compensatory damages, punitive damages, and attorney's fees. The bill effectively bans the drug from the U.S. market while exposing manufacturers to unlimited civil liability.

Why we flagged it

The bill's operative mechanism is twofold: (1) retroactive withdrawal of FDA approval for a specific drug, and (2) creation of a novel federal tort with unusually broad causation language ("attributable, in whole or in part") that exposes manufacturers to civil liability for subjective harms. This is not primarily a safety measure—it is a ban paired with a liability regime designed to deter future use and manufacture.

What the text implies

• The liability standard (harm 'attributable, in whole or in part') is unusually permissive and may allow claims based on correlation rather than causation, potentially exposing manufacturers to liability for harms unrelated to the drug's pharmacology.
• By creating a federal private right of action, the bill shifts enforcement of product safety from the FDA (a regulatory body with scientific expertise) to individual litigation, which may be less reliable at distinguishing genuine drug-caused harm from coincidental health events.

The full analysis lists 5 implications of this text.

Who stands to gain

Litigation firms (class action and individual product liability counsel); Alternative abortion providers (surgical clinics, out-of-state providers)